Two individuals receive first stem cell treatments for autoimmune nerve damage
Two patients have received a new stem cell therapy for an autoimmune condition that impacts both the spinal cord and optic nerves. The treatment is reported by Nature and Scientific American as a significant step in managing severe neurological issues.
Amalgamated from Scientific American (opens in new tab), Nature (opens in new tab), Nature (opens in new tab)
Two individuals have been identified as the first patients to receive a stem cell therapy for an autoimmune disease that damages both the spinal cord and optic nerves, according to reports from Nature and Scientific American. The treatment is intended to address severe conditions where the immune system attacks these critical components of the nervous system.
The reporting indicates that this specific intervention was administered to individuals suffering from symptoms related to significant nerve damage. By utilizing stem cell technology, the therapy aims to manage a condition that typically impacts mobility and vision. Both Nature and Scientific American confirm that these two patients are the first to receive this particular treatment.
According to the publications, the goal of the therapy is to provide long term management of the autoimmune response. The use of stem cells in this context addresses the damage caused by the immune system's interaction with the spinal cord and optic nerves. The reports highlight that these patients are the first to receive this specific procedure for their condition.